Literature DB >> 15832546

Psychological disturbance and sleep disorders in children with neurofibromatosis type 1.

Hilary Johnson1, Luci Wiggs, Gregory Stores, Susan M Huson.   

Abstract

The objective of this study was to explore the behaviour, including sleep patterns, of children with neurofibromatosis type 1 (NF1). For this purpose we designed a cross-sectional descriptive survey conducted by postal enquiry with telephone follow-up. Simonds and Parraga's sleep questionnaire and the Strength and Difficulties Questionnaire were used to screen sleep patterns and behaviours respectively. Information was obtained for 64 children (39 male, mean age 10 y 7 mo, SD 4 y 1 mo, range 3 to 18 y; 57% response rate). There were increased numbers of children with NF1 achieving scores in the borderline and abnormal range for ratings of peer problems (p < 0.001), hyperactivity (p < 0.001), emotional symptoms (p < 0.001), and conduct disorder (p < 0.05). Total difficulties score was also high (p < 0.001) in the NF1 group. Only one group of sleep problems, parasomnias (in particular sleepwalking and sleep terrors), had a higher occurrence (p < or = 0.05) in the NF1 group than in the general population. Within the NF1 group, conduct problems (p < or = 0.05), hyperactivity (p < or = 0.01), emotional problems (p < or = 0.01), and the total difficulties score (p < or = 0.01) were all significantly higher in children with frequent sleep disturbance. We conclude that NF1 is associated with sleep and behavioural problems in a high proportion of children. Psychiatric conditions, e.g. attention-deficit-hyperactivity disorder, may be underdiagnosed on a large scale in children with NF1, and the use of simple screening tools in clinical settings may prove beneficial.

Entities:  

Mesh:

Year:  2005        PMID: 15832546     DOI: 10.1017/s0012162205000460

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  19 in total

1.  Recommendations for the use of common outcome measures in pediatric traumatic brain injury research.

Authors:  Stephen R McCauley; Elisabeth A Wilde; Vicki A Anderson; Gary Bedell; Sue R Beers; Thomas F Campbell; Sandra B Chapman; Linda Ewing-Cobbs; Joan P Gerring; Gerard A Gioia; Harvey S Levin; Linda J Michaud; Mary R Prasad; Bonnie R Swaine; Lyn S Turkstra; Shari L Wade; Keith O Yeates
Journal:  J Neurotrauma       Date:  2011-08-24       Impact factor: 5.269

2.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

3.  Psychometric evaluation of the pediatric and parent-proxy Patient-Reported Outcomes Measurement Information System and the Neurology and Traumatic Brain Injury Quality of Life measurement item banks in pediatric traumatic brain injury.

Authors:  Hilary Bertisch; Frederick P Rivara; Pamela A Kisala; Jin Wang; Keith Owen Yeates; Dennis Durbin; Mark R Zonfrillo; Michael J Bell; Nancy Temkin; David S Tulsky
Journal:  Qual Life Res       Date:  2017-03-07       Impact factor: 4.147

Review 4.  Pediatric sleep questionnaires as diagnostic or epidemiological tools: a review of currently available instruments.

Authors:  Karen Spruyt; David Gozal
Journal:  Sleep Med Rev       Date:  2010-10-08       Impact factor: 11.609

Review 5.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Authors:  Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby
Journal:  J Med Genet       Date:  2006-11-14       Impact factor: 6.318

Review 6.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

7.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

Review 8.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

9.  Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1.

Authors:  Amy K Licis; Alicia Vallorani; Feng Gao; Cynthia Chen; Jason Lenox; Kelvin A Yamada; Stephen P Duntley; David H Gutmann
Journal:  J Child Neurol       Date:  2013-09-23       Impact factor: 1.987

10.  Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review.

Authors:  Carmen Sílvia Miguel; Tiffany M Chaim-Avancini; Maria Aparecida Silva; Mario Rodrigues Louzã
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-25       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.